Pharmaceutical formulations and methods for treating metabolic disorders and liver diseases

By using compounds of general formula I structure and pharmaceutical carriers and diluents in pharmaceutical preparations, the problem of limited tolerance of GIP/GLP-1 dual receptor agonist at high doses is solved, and the fatty liver disease is achieved Effective treatment improves treatment compliance and effectiveness.

CN118946368APending Publication Date: 2024-11-12VIKING THERAPEUTICS INC
View PDF -1 Cites 0 Cited by

Patent Information

Application Number
CN202380028118.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-18
Filing Date
2023-01-11
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing GIP/GLP-1 dual receptor agonists are limited to tolerance due to gastrointestinal adverse events at high doses, which affects the achievement of treatment compliance and effective doses, leading to the challenge of treating fatty liver disease.

Method used

A pharmaceutical preparation has been developed, comprising a compound having the structure of formula I or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier and diluent such as propylene glycol and pH buffering, for the prevention or treatment of fatty liver disease. , including non-alcoholic steatohepatitis and liver fibrosis.

Benefits of technology

By improving the tolerance and bioaccessibility of drugs, the effectiveness of the treatment of fatty liver disease is enhanced, the gastrointestinal side effects are reduced, and the patient compliance and effectiveness of treatment plans are improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005045389990000021
    Figure BDA0005045389990000021
  • Figure BDA0005045389990000041
    Figure BDA0005045389990000041
  • Figure BDA0005045389990000051
    Figure BDA0005045389990000051
Patent Text Reader

Abstract

Disclosed herein are formulations of small molecule GIP / GLP-1 dual receptor agonists and uses thereof.
Need to check novelty before this filing date? Find Prior Art